Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

ICMR and Panacea Biotec aim to finish enrollment for Phase 3 trials of India’s first indigenous dengue vaccine by October ...

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

A paralyzed military veteran is one of seven people in the country to be implanted with an Elon Musk-backed brain chip as ...

Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical trial recruitment.